Affinium doses first patient in AFN-1252 drug trial - Pharmaceutical Business Review.
Affinium Pharmaceuticals has dosed first patient in a multi-center Phase 2 clinical trial investigating oral AFN-1252 in acute bacterial skin & skin structure infections (ABSSSI). AFN-1252, the clinical candidate from the company's FASII program, is designed to selectively target the staphylococcal FabI enzyme. The Phase 2 trial is designed to confirm efficacy and tolerability of 200 mg of oral AFN-1252 dosed twice daily for 5-14 days in patients with staphylococcal skin infections.
